medigraphic.com

2011, Número 4

<< Anterior Siguiente >>

Rev Med MD 2011; 2.3 (4)


Papel de la apoptosis en la respuesta inmune antitumoral

García-Castro B, Olimón- Andalón V, Aguilar-Lemarroy A

Idioma: Español
Referencias bibliográficas: 42
Paginas: 206-210
Archivo PDF: 564.70 Kb.


RESUMEN

La apoptosis es un programa de muerte celular finamente regulado, esencial en el mantenimiento de la homeostasis de los tejidos ya que se encarga de eliminar aquellas células que no son necesarias o que son dañinas para el organismo. Los defectos en las vías de señalización apoptóticas promueven una proliferación celular aberrante y una acumulación de defectos genéticos, lo que conlleva a la tumorigénesis y frecuentemente confiere a las células cancerosas resistencia a las drogas quimioterapéuticas. Por tales motivos, la regulación de la apoptosis es esencial para mantener el balance entre las señales de supervivencia y muerte celular requeridas para prevenir una enfermedad. Son varias las vías de señalización que regulan la inducción o inhibición de la apoptosis, dentro de las principales proteínas reguladoras se encuentran miembros de la familia BCL-2, proteínas inhibidoras de la apoptosis (IAP) y la proteína c-FLIP. En esta revisión se señalan los mecanismos por los cuales estas proteínas regulan la apoptosis, además de profundizar en las alteraciones que más frecuentemente se han observado en la inhibición de las señales apoptóticas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.

  2. Krammer PH, Arnold R, Lavrik IN. Life and death in peripheral T cells. Nat Rev Immunol 2007 Jul;7(7):532-42.

  3. Plati J, Bucur O, Khosravi-Far R. Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011 Apr;3(4):279-96.

  4. Fulda S. Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol 2010;2010:370835.

  5. Plati J, Bucur O, Khosravi-Far R. Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities. J Cell Biochem 2008 Jul 1;104(4):1124-49.

  6. Fan TJ, Han LH, Cong RS, Liang J. Caspase family proteases and apoptosis. Acta Biochim Biophys Sin (Shanghai) 2005 Nov;37(11):719-27.

  7. Moffitt KL, Martin SL, Walker B. From sentencing to execution--the processes of apoptosis. J Pharm Pharmacol 2010 May;62(5):547-62.

  8. Alenzi FQ, Lotfy M, Wyse R. Swords of cell death: caspase activation and regulation. Asian Pac J Cancer Prev 2010;11(2):271-80.

  9. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006 Aug 7;25(34):4798-811.

  10. Krammer PH, Kaminski M, Kiessling M, Gulow K. No life without death. Adv Cancer Res 2007;97:111-38.

  11. Vaux DL. Apoptogenic factors released from mitochondria. Biochim Biophys Acta 2011;1813(4):546-50.

  12. Gimenez-Bonafe P, Tortosa A, Perez-Tomas R. Overcoming drug resistance by enhancing apoptosis of tumor cells. Curr Cancer Drug Targets 2009 May;9(3):320-40.

  13. Wilson TR, Johnston PG, Longley DB. Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 2009 May;9(3):307-19.

  14. Cascino I, Papoff G, Eramo A, Ruberti G. Soluble Fas/Apo-1 splicing variants and apoptosis. Front Biosci 1996 Jan 1;1:d12-d18.

  15. Abbasova SG, Vysotskii MM, Ovchinnikova LK, Obusheva MN, Digaeva MA, Britvin TA, et al. Cancer and soluble FAS. Bull Exp Biol Med 2009 Oct;148(4):638-42.

  16. Aguilar-Lemarroy A, Romero-Ramos JE, Olimon-Andalon V, Hernandez-Flores G, Lerma-Diaz JM, Ortiz-Lazareno PC, et al. Apoptosis induction in Jurkat cells and sCD95 levels in women's sera are related with the risk of developing cervical cancer. BMC Cancer 2008;8:99.

  17. Bertoni F, Conconi A, Carobbio S, Realini C, Codegoni AM, Zucca E, et al. Analysis of Fas/CD95 gene somatic mutations in ovarian cancer cell lines. Int J Cancer 2000 May 1;86(3):450.

  18. Boldrini L, Loggini B, Gisfredi S, Zucconi Y, Baldinotti F, Fogli A, et al. Mutations of Fas (APO-1/CD95) and p53 genes in nonmelanoma skin cancer. J Cutan Med Surg 2003 Mar;7(2):112-8.

  19. Park WS, Oh RR, Kim YS, Park JY, Lee SH, Shin MS, et al. Somatic mutations in the death domain of the Fas (Apo-1/CD95) gene in gastric cancer. J Pathol 2001 Feb;193(2):162-8.

  20. Gutierrez LS, Eliza M, Niven-Fairchild T, Naftolin F, Mor G. The Fas/Fasligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res Treat 1999 Apr;54(3):245-53.

  21. Ryan AE, Shanahan F, O'Connell J, Houston AM. Fas ligand promotes tumor immune evasion of colon cancer in vivo. Cell Cycle 2006 Feb;5(3):246-9.

  22. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol Med Today 1998 Feb;4(2):63-8.

  23. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995 Dec;3(6):673-82.

  24. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996 May 31;271(22):12687-90.

  25. Newsom-Davis T, Prieske S, Walczak H. Is TRAIL the holy grail of cancer therapy? Apoptosis 2009 Apr;14(4):607-23.

  26. Falschlehner C, Emmerich CH, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007;39(7-8):1462-75.

  27. Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res 2008 Dec;6(12):1861-71.

  28. Zhang L, Fang B. Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 2005 Mar;12(3):228-37.

  29. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene 2002 Apr 4;21(15):2283-94.

  30. Ndozangue-Touriguine O, Sebbagh M, Merino D, Micheau O, Bertoglio J, Breard J. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene 2008 Oct 9;27(46):6012-22.

  31. Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 2007 Dec 15;13(24):7254-63.

  32. Giam M, Huang DC, Bouillet P. BH3-only proteins and their roles in programmed cell death. Oncogene 2008 Dec;27 Suppl 1:S128-S136.

  33. Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, et al. BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science 2010 Dec 3;330(6009):1390-3.

  34. Pop C, Salvesen GS. Human caspases: activation, specificity, and regulation. J Biol Chem 2009 Aug 14;284(33):21777-81.

  35. Mace PD, Shirley S, Day CL. Assembling the building blocks: structure and function of inhibitor of apoptosis proteins. Cell Death Differ 2010 Jan;17(1):46-53.

  36. Eckelman BP, Salvesen GS, Scott FL. Human inhibitor of apoptosis proteins: why XIAP is the black sheep of the family. EMBO Rep 2006 Oct;7(10):988-94.

  37. Fulda S. Inhibitor of apoptosis proteins in hematological malignancies. Leukemia 2009 Mar;23(3):467-76.

  38. Scaffidi C, Schmitz I, Krammer PH, Peter ME. The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 1999 Jan 15;274(3):1541-8.

  39. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, et al. Inhibition of death receptor signals by cellular FLIP. Nature 1997 Jul 10;388(6638):190-5.

  40. Chang DW, Xing Z, Pan Y, Algeciras-Schimnich A, Barnhart BC, Yaish-Ohad S, et al. c-FLIP(L) is a dual function regulator for caspase-8 activation and CD95-mediated apoptosis. EMBO J 2002 Jul 15;21(14):3704-14.

  41. Bagnoli M, Canevari S, Mezzanzanica D. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. Int J Biochem Cell Biol 2010 Feb;42(2):210-3.

  42. Horak P, Pils D, Kaider A, Pinter A, Elandt K, Sax C, et al. Perturbation of the tumor necrosis factor--related apoptosis-inducing ligand cascade in ovarian cancer: overexpression of FLIPL and deregulation of the functional receptors DR4 and DR5. Clin Cancer Res 2005 Dec 15;11(24 Pt 1):8585-91.




2020     |     www.medigraphic.com